跳至主要内容
临床试验/KCT0000025
KCT0000025进行中(未招募)未知

CoMparison of TriflusAl and Clopidogrel Effect in Secondary Prevention of STroke Based on the CytochRome P450 2C19 GenOtyping; MAESTRO study

Yonsei University Health System, Gangnam Severance Hospital0 个研究点目标入组 1,080 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
1,080

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
20(Year) 至 o Limit(—)
性别
All

入选标准

  • 1. Patients who have non-caridogenic ischemic stroke of TOAST classification within 30 days prior to screening
  • 2. = 20 years of age; adult, at the date of signing the informed consent
  • 3. Written informed consent

排除标准

  • 1. History for bleeding tendency or recent major bleeding within 2 weeks
  • 2. Chronic liver disease (ALT>100 or AST>100) or renal dysfunction (creatinine>4.0mg/dl)
  • 3. Thrombocytopenia (platelet<100,000mm3)
  • 4. Any contraindication of antiplatelet agent
  • 5. Severe congestive heart failure
  • 6. Patients who need to take anticoagulants or two more antiplatelet agents
  • 7. Severe concomitant disease with the expected survival less than 2 years
  • 8. Pregnant or nursing
  • 9. Any drug clinical trials within 30 days of signing the informed consent

研究者

发起方
Yonsei University Health System, Gangnam Severance Hospital

相似试验